Skip to main content

Pacira BioSciences, Inc.

corporate_fare Company Profile

Pacira BioSciences, Inc.

PCRX·NASDAQ·Life Sciences·CIK 0001396814

Pacira BioSciences, Inc. is a Delaware corporation that serves as the holding company for its California operating subsidiary, Pacira Pharmaceuticals, Inc. The company's mission is to deliver innovative, non-opioid pain therapies. Pacira BioSciences, Inc. was incorporated in Delaware in December 2006 as Blue Acquisition Corp., changing its name to Pacira, Inc. in June 2007, then to Pacira Pharmaceuticals, Inc. in October 2010, and finally to Pacira BioSciences, Inc. in April 2019. Its principal executive offices and corporate headquarters are located in Brisbane, California. The company has expanded through several acquisitions. In March 2007, it acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.). In April 2019, Pacira BioSciences, Inc. acquired MyoScience, Inc., a privately held medical technology company. This was followed by the acquisition of Flexion Therapeutics, Inc., a publicly traded biopharmaceutical company, in November 2021. Most recently, in February 2025, the company acquired GQ Bio Therapeutics GmbH, a privately-held biopharmaceutical company. Key trademarks and service marks owned by Pacira include Pacira®, EXPAREL®, ZILRETTA®, iovera®°, and the Pacira logo.

Pacira BioSciences, Inc. (NASDAQ:PCRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 52 items for PCRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PCRX spans 8-K, SC 14D9/A, 10-Q, SC 14D9.

Recent high-impact activity:

  • Viatris Closes $36.50-a-Share Takeover of Pacira
  • Ninth Circuit Reverses Pacira's EXPAREL Royalty Win, Reviving RDF Royalty on 200-Liter Process
  • Pacira Discloses Two Merger Suits and 15 Demand Letters Over 14D-9 Disclosures
  • Pacira Q3 Net Income Jumps to $28.5M as Viatris Tender Offer Runs
  • Pacira Cancels Q3 Earnings Release and Withdraws 2026 Guidance Pending Viatris Deal

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$726.41M
Net Income
$7.03M
Diluted EPS
$0.16
Op. Cash Flow
$151.99M
Free Cash Flow
$136.66M
Gross Profit
$576.66M
Operating Income
$19.19M
Cash & Equivalents
$158.54M
Total Debt
$372.19M
Debt / Equity
0.54×
Net Margin
1.0%
Shares Outstanding
41.12M sh
Source: 10-K · filed 2026-02-26 · accession 0001628280-26-012297

Short Interest & Short Volume

3.91 days to cover

FINRA reported short interest of 3,348,320 shares in PCRX as of the October 30, 2026 settlement, a 21.4% decrease from the prior period — about 3.9 days to cover at its recent average daily volume. On November 16, 2026, 68.9% of PCRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,348,320 shares as of October 30, 2026
Change vs prior period▼ 21.4%
Days to cover3.91 at avg daily volume of 855,601
Daily short volume (FINRA facilities)68.9% of 315,634 shares on November 16, 2026
3-day average short volume47.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with P →
$36.49
52-week range · as of 2026-11-12 $18.8 – $36.66
Market cap
$1.46B
Volume
1.8M (0.8× avg)
3-mo avg 2.2M
Last traded · 2026-11-18

show_chartPrice Chart

Loading chart...

feed PCRX - Latest Insights

PCRX
Nov 17, 2026, 8:50 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $36.49
Real-time Price: $36.49 info
Change: $0 (0%) info
Market Cap: $1.463B info
PCRX
Nov 12, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.46
Real-time Price: $36.49 info
Change: +$0.030 (+0.08%) info
Market Cap: $1.463B info
PCRX
Nov 12, 2026, 4:15 PM EST
Filing Type: SC 14D9/A
Importance Score:
7
Price at Filing: $36.46
Real-time Price: $36.49 info
Change: +$0.030 (+0.08%) info
Market Cap: $1.463B info
PCRX
Nov 05, 2026, 4:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.49 info
Change: +$0.070 (+0.19%) info
Market Cap: $1.463B info
PCRX
Nov 05, 2026, 4:33 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $36.42
Real-time Price: $36.49 info
Change: +$0.070 (+0.19%) info
Market Cap: $1.463B info
PCRX
Oct 30, 2026, 8:32 AM EDT
Filing Type: SC 14D9
Importance Score:
8
Price at Filing: $36.35
Real-time Price: $36.49 info
Change: +$0.140 (+0.39%) info
Market Cap: $1.463B info
PCRX
Oct 13, 2026, 5:54 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $36.38
Real-time Price: $36.49 info
Change: +$0.110 (+0.30%) info
Market Cap: $1.463B info
PCRX
Oct 08, 2026, 9:24 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $36.34
Real-time Price: $36.49 info
Change: +$0.150 (+0.41%) info
Market Cap: $1.463B info
PCRX
Oct 08, 2026, 7:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $25.72
Real-time Price: $36.49 info
Change: +$10.77 (+42%) info
Market Cap: $1.463B info
PCRX
Aug 04, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $27.62
Real-time Price: $36.49 info
Change: +$8.87 (+32%) info
Market Cap: $1.463B info
PCRX
Aug 04, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.62
Real-time Price: $36.49 info
Change: +$8.87 (+32%) info
Market Cap: $1.463B info
PCRX
Aug 04, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $27.62
Real-time Price: $36.49 info
Change: +$8.87 (+32%) info
Market Cap: $1.463B info
PCRX
Jul 27, 2026, 8:02 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $26.00
Real-time Price: $36.49 info
Change: +$10.49 (+40%) info
Market Cap: $1.463B info
PCRX
Jun 30, 2026, 7:31 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $25.59
Real-time Price: $36.49 info
Change: +$10.90 (+43%) info
Market Cap: $1.463B info
PCRX
Jun 30, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $25.56
Real-time Price: $36.49 info
Change: +$10.93 (+43%) info
Market Cap: $1.463B info
PCRX
Jun 11, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.36
Real-time Price: $36.49 info
Change: +$13.13 (+56%) info
Market Cap: $1.463B info
PCRX
Jun 04, 2026, 4:24 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $22.67
Real-time Price: $36.49 info
Change: +$13.82 (+61%) info
Market Cap: $1.463B info
PCRX
Jun 01, 2026, 5:14 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $22.96
Real-time Price: $36.49 info
Change: +$13.53 (+59%) info
Market Cap: $1.463B info
PCRX
May 28, 2026, 5:28 PM EDT
Filing Type: DFAN14A
Importance Score:
9
Price at Filing: $23.68
Real-time Price: $36.49 info
Change: +$12.81 (+54%) info
Market Cap: $1.463B info
PCRX
May 28, 2026, 4:34 PM EDT
Filing Type: DEFA14A
Importance Score:
9
Price at Filing: $23.68
Real-time Price: $36.49 info
Change: +$12.81 (+54%) info
Market Cap: $1.463B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets